Cargando…

Quality by Design Approach for Development and Characterisation of 
Solid Lipid Nanoparticles of Quetiapine Fumarate

BACKGROUND: Quetiapine fumarate, a 2(nd) generation anti-psychotic drug has oral bioavailability of 9% because of hepatic first pass metabolism. Reports suggest that co-administration of drugs with lipids affects their absorption pathways, enhances lymphatic transport thus bypassing hepatic first-pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Agarwal, Shweta, Murthy, Rayasa S. Ramachandra, Harikumar, Sasidharan Leelakumari, Garg, Rajeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967136/
https://www.ncbi.nlm.nih.gov/pubmed/31429691
http://dx.doi.org/10.2174/1573409915666190722122827
Descripción
Sumario:BACKGROUND: Quetiapine fumarate, a 2(nd) generation anti-psychotic drug has oral bioavailability of 9% because of hepatic first pass metabolism. Reports suggest that co-administration of drugs with lipids affects their absorption pathways, enhances lymphatic transport thus bypassing hepatic first-pass metabolism resulting in enhanced bioavailability. OBJECTIVE: The present work aimed at developing, and characterising potentially lymphatic absorbable Solid Lipid Nanoparticles (SLN) of quetiapine fumarate by Quality by Design approach. METHODS: Hot emulsification followed by ultrasonication was used as a method of preparation. Precirol ATO5, Phospholipon 90G and Poloxamer 188 were used as a lipid, stabilizer and surfactant respectively. 
A3(2) Central Composite design optimised the 2 independent variables, lipid concentration and stabilizer concentration and assessed their effect on percent Entrapment Efficiency (%EE: Y1). The lyophilized SLNs were studied for stability at 5 ±3(ο)C and 25 ± 2(ο)C/60 ± 5% RH for 3 months. RESULTS: The optimised formula derived for SLN had 270mg Precirol ATO5 and 107mg of Phospholipon 90G giving %EE of 76.53%. Mean particle size was 159.8nm with polydispersity index 0.273 and zeta potential -6.6mV. In-vitro drug release followed Korsmeyer-Peppas kinetics (R(2)=0.917) with release exponent n=0.722 indicating non-Fickian diffusion. Transmission electron microscopy images exhibited particles to be spherical and smooth. Fourier-transform infrared spectroscopy, differential scanning calorimetry and X-ray diffraction studies ascertained drug-excipient compatibility. Stability studies suggested 5(ο)C as appropriate temperature for storage and preserving important characteristics within acceptable limits. CONCLUSION: Development and optimisation by Quality by Design were justified as it yielded SLN having acceptable characteristics and potential application for intestinal lymphatic transport.